CorMedix (CRMD) Form 4 CorMedix / MICHAEL W GEORGE ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

GEORGE MICHAEL W

(Last) (First) (Middle)

C/O CORMEDIX INC.

1430 HIGHWAY 206, SUITE 200

(Street)

BEDMINSTER NJ 07921

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2016

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy Common Stock)	$2.11							(1)	04/05/2024	Common Stock	15,000		15,000	D
Stock Option (Right to buy Common Stock)	$2.79							(2)	02/27/2024	Common Stock	30,000		30,000	D
Stock Option (Right to buy Common Stock)	$5.62							(2)	03/01/2025	Common Stock	50,000		50,000	D
Phantom Stock	$0(3)							(3)	(3)	Common Stock	1,847		1,847	D
Phantom Stock	$0(3)							(3)	(3)	Common Stock	1,176		1,176	D
Phantom Stock	$0(3)							(3)	(3)	Common Stock	2,459		2,459	D
Phantom Stock	$0(3)							(3)	(3)	Common Stock	3,125		3,125	D
Stock Option (Right to buy Common Stock)	$1.91							(2)	02/21/2026	Common Stock	90,000		90,000	D
Phantom Stock	$0(3)							(3)	(3)	Common Stock	3,968		3,968	D
Phantom Stock	$0(3)							(3)	(3)	Common Stock	2,767		2,767	D
Phantom Stock	$0(3)	08/12/2016		A		4,335(4)		(3)	(3)	Common Stock	4,335	$0	4,335	D

Explanation of Responses:

1. 5,000 vest upon completion of an April 2014 milestone; 10,000 vest upon completion of another milestone by the third quarter of 2014.

2. These options vest in full on the first anniversary of the date of grant.

3. Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock on the tenth business day of January of the year following the reporting person's termination of service as a director.

4. These shares were credited automatically to the reporting person's account pursuant to the reporting person's election to defer the receipt of cash compensation of director fees.

	/s/ Alexander M. Donaldson, by Power of Attorney	08/16/2016
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.